Seronegative NMO: A sensitive AQP4 antibody test clarifies clinical features and next challenges

Neurology

Volumn 80, Issue 24, 2013, Pages 2176-2177

  Fujihara, Kazuo ^a   Leite, Maria Isabel ^b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

AMINO ACID SEQUENCE; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; CELL ASSAY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; EDITORIAL; ETHNICITY; FLOW CYTOMETRY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; MYELITIS; MYELOOPTIC NEUROPATHY; NEURITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SEX DIFFERENCE; VISUAL IMPAIRMENT;

AQUAPORIN 4; AUTOANTIBODIES; FEMALE; HUMANS; MALE; NEUROMYELITIS OPTICA;

EID: 84879105066     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318296ea22     Document Type: Editorial

References (10)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
2. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
3. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 2013;80:2194-2200.
4. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
5. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-671.
6. Mader S, Lutterotti A, Di Pauli F, et al. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One 2010;5:e10455.
7. McKeon A, Pittock SJ, Lennon VA. CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology 2011;76:1108-1110.
8. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-1277.
9. Fujihara KM, Nakashima I, Takahashi T, et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 2012;3:58-73.
10. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-643.